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Excitatory amino acid (EAA) receptor-mediated events have recently been implicated in dopaminergic mechanisms of neurotoxicity. 2,4,5-Tri- 
hydroxyphenylalanine (6-hydroxy-DOPA, TOPA), the ortho-hydroxylated derivative of the dopamine precursor 2,4-dihydroxyphenylalanine (L- 
DOPA), has recently been reported to have neurotoxic properties which are blocked by CNQX, a specific antagonist of the AMPA class of non-N- 
methyl-o-aspartate (non-NMDA) EAA receptors. We report here that 6-hydroxy-DOPA is a selective displacer of [aH]AMPA binding in rodent 
brain. 6-Hydroxy-DOPA was as potent as kainate in displacing [3H]AMPA binding, with an IC5o value of 32/tM. Ineffective displacers of [3H]AMPA 
binding included dopamine, 6-hydroxydopamine, L-DOPA, D-DOPA, carbidopa, DOPAC, fl-methylamino-L-alanine, 2,4-dihydroxyphenylacetyl-L- 
asparagine, homogentisic acid, 2,4-dihydroxyphenylacetic acid, amantadine, and threo-DOPS. 6-Hydroxy-DOPA (100/tM) also displaced 20% of 
[aH]kainate binding, but did not displace binding to NMDA, phencyclidine (PCP), or dopaminergic (D1 and Dz) receptors. These data raise the 
possibility that 6-hydroxy-DOPA or another abnormal metabolite of L-DOPA could act as an excitotoxic agent via action at AMPA receptors. 
Given that non-NMDA receptors are postulated to play a role in neurotoxic events, these data provide an additional mechanism via which EAA 
receptor-mediated events could produce neurodegeneration in areas of brain with dopaminergic innervation. 
Abnormal activation of excitatory amino acid (EAA) 
receptors has been implicated in the pathophysiology of 
various types of neurotoxic events including epilepsy [5], 
neuronal damage resulting from hypoxia-ischemia [15], 
olivopontocerebellar atrophy [13], and Alzheimer's dis- 
ease [9, 11]. Huntington's disease and Parkinson's dis- 
ease are neurodegenerative diseases in which dopaminer- 
gic systems or their targets are preferentially affected. 
EAA receptor-mediated mechanisms have recently been 
implicated in the pathophysiology of both Huntington's 
disease [4] and Parkinson's disease [8, 17]. While the re- 
gional specificity of the neuropathologic changes seen in 
Huntington's and Parkinson's diseases is as yet unex- 
plained, recent observations emphasize the importance 
of interactions between dopaminergic and EAA systems. 
MK-801, a specific antagonist of the N-methyl-D-aspar- 
tate (NMDA) subtype of EAA receptor, blocks metham- 
phetamine-induced nigrostriatal toxicity [16]. In addi- 
tion, several NMDA antagonists have been shown to 
block the neurotoxic effects of 1-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine (MPTP) in the substantia 
nigra [17]. 
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Olney et al. [10] recently reported that L-DOPA and 
its ortho-hydroxylated derivative 6-hydroxy-DOPA pro- 
duced neurotoxic damage of the chick retina in a manner 
similar to that induced by the EAA agonists kainate and 
quisqualate. The non-NMDA receptor antagonist 6- 
nitro-7-cyano-quinoxaline-2,3-dione (CNQX) blocked 
neurotoxic effects of all the tested compounds, but the 
NMDA receptor antagonist MK-801 did not. In addi- 
tion, 6-hydroxy-DOPA produced depolarizations of cul- 
tured rat hippocampal neurons which were blocked by 
CNQX but not by the NMDA receptor antagonist 2- 
amino-5-phosphonovalerate (APV) [1, 10, 14]. These 
results clearly indicated a potential interaction of 6- 
hydroxy-DOPA and AMPA receptors. The present 
experiments were directed towards this question. 
Autoradiographic binding assays were performed 
according to previously published methods (Table I). 
Briefly, the following materials were employed (receptor 
type, [3H]ligand, buffer, incubation conditions, rinse 
time): ionotropic quisqualate/AMPA receptors, 
[aH]AMPA, 50 mM Tris-HCl+2.5 mM CAC12+30 mM 
KSCN pH 7.2, 45 min at 4°C, < 10 s in buffer followed 
by 2.5% glutaraldehyde in acetone; kainate receptors, 
[3H]kainate, 50 mM Tris-acetate, 45 min at 4°C, < 10 s 
in buffer followed by 2.5% glutaraldehyde in acetone; 
56 
TABLE I 
AUTORADIOGRAPHIC BINDING ASSAYS 
Numbers represent percentage of  control binding for each assay _+ S.E.M. (n = 4 animals). All compounds tested at a concentration of 100/tM. n.t., 
not tested. 
Receptor assay: AMPA Kainate NMDA PCP D~ Receptors D2 Receptors 
Ligand: [3H]AMPA [3H]Kainate [3H]Glutamate [3H]MK-801 [~H]SCH-23390 [3H]Spiperone 
Ligand concentration: 15 nM 60 nM 65 nM 5 nM 495 pM 250 pM 
Specific activity (Ci/mmol): 60 58 46 22.5 83 93 
Non-specific binding: 1 mM Glu 100/iM kainate 1 mM NMDA 5 ¢tM MK-801 10/zM cis-flupenthixol 500/tM dopamine 
6-Hydroxy-DOPA 20 + 1 80 + 3 109 __+ 19 94 + 6 103 + 3 105 + 12 
Quisqualate 2 _+ I 2 + 0 44 + 14 n.t. 91 + 14 107 + 11 
AMPA 1+0 n.t. n.t. n.t. 90+2 119_+20 
BMAA 102__+8 89_+7 118+29 100_+7 100+4 99_+ 14 
2,4-Dihydroxyphenylacetyl-L-asparagine 100-t-4 101 +9 134+28 99_+6 106+2 95+ I I 
Homogentisic acid 106 + 6 99 _+ 6 107 + 27 93 + 9 119 + 7 95 + 14 
2,4-Dihydroxyphenylacetic acid 101 _ 4 85 _+ 2 95 -+ 26 98 + 9 102 + 3 90 + 18 
Dopamine 89 _+ 5 89 -+ 2 1 l0 -+ 27 93 _+ 5 9 _+ 1 
6-OH-Dopamine 89 _+ 3 90 _+ 3 110 + 29 98 _+ 5 9 ! _+ 9 75 _+ 5 
L-DOPA 92_+2 81 _+7 90-+24 92-+4 105_+9 51 _+9 
t~-DOPA 84+ 10 87_+2 86_+ 16 99_+5 109_+5 80._ 14 
threo-DOPS 103_+ 1 100_+5 108_+28 96-+7 117_+6 78_+ 13 
Amantadine 101 _+ 9 79 _+ 14 118 _+ 25 73 -+ 8 106 -+ 1 69 _+ 7 
Carbi-DOPA 99 _+ 3 92 -+ 8 143 -+ 43 105 -+ 8 60 -+ 5 51 _+ 4 
DOPAC 99_+8 86_+8 137_+33 99_+8 103-+3 94-+5 
NMDA receptors, [3H]glutamate, 50 mM Tris-acetate, 
45 rain at 4°C, < 10 s in buffer followed by 2.5% glutaral- 
dehyde in acetone; phencyclidine (PCP) site within the 
NMDA channel, [3H]MK-801, 50 mM Tris-Ac, pH 7.4, 
120 rain at room temperature, 80 min in cold buffer; D, 
dopamine receptors, [3H]SCH-23390, 25 mM Tris- 
HCI+ 100 mM NaCI+ 1 mM MgCI 2 + 1/tM pargyline in 
0.001% ascorbate, 150 rain at room temperature, 10 min 
in cold buffer; D 2 dopamine receptors, [3H]spiperone, 25 
mM Tris-HCl+100 mM NaCI+I  mM MgCI2+I /tM 
pargyline + 100 nM mianserin in 0.001% ascorbate, 150 
min at room temperature, 10 rain in cold buffer. Dried 
sections were placed in X-ray cassettes with appropriate 
radioactive standards [12] and apposed to Amersham 
Hyperfilm. The film was exposed to the tissue sections 
for 14-21 days at 4°C, then developed, fixed and dried. 
The optical densities of the resultant film images were 
determined using a commercially available computer- 
based image analysis system (Imaging Research, Inc., St. 
Catharine's, Ont. Canada). Ten to twenty-five readings 
were averaged from each region of interest. The amount 
of radioactivity was determined by a computer-gener- 
ated polynomial regression analysis which compared 
film densities produced by the tissue sections to those 
produced by the radioactive standards. All data pre- 
sented were analyzed densitometrically from autoradio- 
graphic images. 
6-Hydroxy-DOPA (100 pM) displaced 80% of 
[3H]AMPA binding in rat striatum (Table I). Quisqua- 
late and AMPA (100 /~M) completely displaced 
[3H]AMPA binding, but [3H]AMPA binding was dis- 
placed less than !1% by L-DOPA, S(-)-~-hydrazino- 
3,4-dihydro-~-methylbenzenepropanoic acid (carbi- 
DOPA), 3,4-dihydroxyphenylacetic acid (DOPAC), 
amantadine, DL-threo-3,4-dihydroxyphenylserine (threo- 
DOPS), dopamine, 6-hydroxydopamine, 2,4-dihydroxy- 
phenylacetyl-L-asparagine, homogentisic acid, or 2,4- 
dihydroxyphenylacetic acid. D-DOPA displaced 16% of 
[3H]AMPA binding. 6-Hydroxy-DOPA (ICso = 32/.tM) 
was as potent as kainate in displacing [3H]AMPA bind- 
ing (ICso=48 /tM). Other effective displacers of 
[3H]AMPA binding included the AMPA receptor antag- 
onist CNQX (ICso=476 riM), fl-N-oxalylamino-L-ala- 
nine (BOAA) (IC5o=1.2 /tM), and quisqualate 
(ICso = 47 nM). 
6-Hydroxy-DOPA also displaced 20% of striatal 
[3H]kainate binding, as did L-DOPA. 6-Hydroxy-DOPA 
had no effect on NMDA-sensitive [3H]glutamate bind- 
ing, [3H]MK-801 binding, [3H]SCH-23390 (D 1 receptor) 
binding or [3H]spiperone (D 2 receptor) binding (Table I). 
Other structurally similar compounds, when tested at a 
concentration of 100/tM, failed to displace significant 
amounts of [3H]AMPA binding. Notably, L-DOPA dis- 
placed only 9% of [3H]AMPA binding, indicating that 
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Fig. 1. Displacers of [3H]AMPA binding in rat striatum: quisqualate 
(©); CNQX (11); BOAA (A); 6-hydroxy-DOPA (0);  kainate ([]). 
Points represent the means of data from 3 animals. Standard errors of 
the mean were less than 15%. Concentration of [3H]AMPA was 37 nM. 
6-Hydroxy-DOPA has been shown to be a potent 
excitant of frog spinal neurons and a potent convulsant 
when injected intraventricularly in rats [2]. Olney et al. 
[10] reported that the dopamine precursor L-DOPA and 
its ortho-hydroxylated analogue 6-hydroxy-DOPA pro- 
duced neurotoxic damage of the chick retina in a fashion 
reminiscent of EAA-induced neurotoxicity. While 6- 
hydroxy-DOPA is not normally found in mammalian 
brain, it can be generated from L-DOPA via the action 
of tyrosinase [7]. It is also possible that other pathways 
for the abnormal hydroxylation of L-DOPA could pro- 
duce 6-hydroxy-DOPA. For example, manganese ions 
can catalyze the formation of 6-hydroxydopamine from 
dopamine. Although 6-hydroxy-DOPA can be con- 
verted to the dopamine neurotoxin 6-hydroxydopamine, 
injections of 6-hydroxy-DOPA, which permeates the 
blood-brain barrier, do not lead to depletions of striatal 
dopamine [6]. In the present study, 6-hydroxydopamine 
was not an effective displacer of EAA receptor binding. 
Rosenberg et al. [14] recently demonstrated that 6- 
hydroxy-DOPA oxidizes in solutions of physiologic pH 
to form a compound which is a neurotoxin and a non- 
NMDA receptor agonist. They concluded that the active 
compound was likely to be an oxidation product of 6- 
hydroxy-DOPA rather than 6-hydroxy-DOPA itself. 
Although in the present study 6-hydroxy-DOPA was 
dissolved in solutions containing 1 mM ascorbate and 
the [3H]AMPA binding assay was performed at 4°C, we 
cannot exclude the possibility that oxidation occurred. 
Some degree of oxidation of 6-hydroxy-DOPA surely 
occurred, as evidenced by the change of solution color 
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from clear to reddish orange. Displacement of 
[aH]AMPA binding in our study may have then been due 
to the presence of an oxidized metabolite of 6-hydroxy- 
DOPA, rather than 6-hydroxy-DOPA itself. Since 6- 
hydroxy-DOPA oxidizes rapidly at physiologic pH, the 
present results are relevant in that a similar oxidation 
reaction is likely to occur in neural tissues. 
Recent studies using chick retina preparations have 
demonstrated that 6-hydroxy-DOPA has neurotoxic 
properties [10, 14]. Electrophysiological responses and 
neurotoxic damage produced by 6-hydroxy-DOPA were 
blocked by the specific non-NMDA receptor EAA 
antagonist CNQX and not by the NMDA receptor 
antagonist APV, suggesting a specific involvement of 
non-NMDA EAA receptors [1, 10]. The present study 
confirms that 6-hydroxy-DOPA or a rapidly produced 
metabolite thereof selectively interacts with AMPA 
receptors and, to a lesser extent, kainate receptors. Both 
of these receptor types have been implicated in neuro- 
toxic phenomena [3, 18]. Given that 6-hydroxy-DOPA 
can be produced by human melanocyte tyrosinase [7], 
the possibility is raised that 6-hydroxy-DOPA or anoth- 
er abnormal metabolite of the catecholaminergic syn- 
thetic pathway could act as an endogenous neurotoxin. 
If such a neurotoxin were selectively generated only by 
catecholaminergic neurons, these same neurons or their 
target neurons would be selectively vulnerable to EAA 
receptor-mediated degeneration. Taken together, these 
observations provide a plausible mechanism for the re- 
gional specificity of neuronal death in both Huntington's 
disease and Parkinson's disease. 
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